Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK4 | Q13043 | 10/20 | 0.63 |
| ▸ | STK3 | Q13188 | 10/20 | 0.63 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30295792 | 0.78 | LRRK2 (0.67) | STK4STK3LRRK2ALDH1A1PDE10A | |
| SCHEMBL15401357 | 0.77 | LRRK2 (1.00) | STK4STK3LRRK2 | |
| SCHEMBL31301551 | 0.76 | LMNA (0.74) | STK4STK3LRRK2KDM4EALDH1A1 | |
| SCHEMBL30295809 | 0.72 | LMNA (0.46) | STK4STK3LRRK2ALDH1A1HTT | |
| SCHEMBL30295802 | 0.72 | LRRK2 (0.67) | STK4STK3LRRK2PDE10ACNR2 | |
| SCHEMBL30295852 | 0.70 | PDE10A (0.50) | STK4STK3LRRK2KDM4EALDH1A1 | |
| SCHEMBL30295705 | 0.70 | LRRK2 (0.71) | STK4STK3LRRK2 | |
| SCHEMBL30295756 | 0.70 | LRRK2 (0.79) | STK4STK3LRRK2 | |
| SCHEMBL30295816 | 0.69 | LMNA (0.47) | STK4STK3LRRK2KDM4EALDH1A1 | |
| SCHEMBL30295742 | 0.68 | STK4 (0.46) | STK4STK3LRRK2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | STK3, STK4, STK36 | STK4 2/4885STK3 1/4885LRRK2 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.